New drug aims to keep rare nerve disease in check long-term
NCT ID NCT05405361
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is a long-term follow-up for people with multifocal motor neuropathy, a rare condition that causes muscle weakness. It tests the safety and effectiveness of a drug called ARGX-117, given intravenously. The trial includes 51 adults who previously took part in an earlier study, and it involves both double-blinded and open-label treatment periods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARGX-117
What this could lead to
If it works, this could provide a long-term treatment option to control muscle weakness in people with multifocal motor neuropathy.
What could go wrong
This is a small, early-phase extension study with only 51 participants, so results may not apply to everyone. Long-term safety and effectiveness are still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIFOCAL MOTOR NEUROPATHY (MMN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Sint-Lucas
Ghent, 9000, Belgium
-
Austin Neuromuscular Center
Austin, Texas, 78759, United States
-
Azienda Ospedaliera Sant' Andrea
Rome, 00189, Italy
-
Azienda Ospedaliero Universitaria Pisana
Pisa, 56126, Italy
-
CHU Bordeaux - Groupe Hospitalier Pellegrin
Bordeaux, 33076, France
-
CHU de Nice
Nice, 06001, France
-
HonorHealth Neurology
Scottsdale, Arizona, 85251, United States
-
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, 46026, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital de La Santa Creu i Sant Pau
Barcelona, 08041, Spain
-
Hôpital Roger Salengro (CHU de Lille)
Lille, 59037, France
-
Hôpital de la Pitié Salpétrière
Paris, 75651, France
-
IRCCS Humanitas Research Hospital
Rozzano, 20089, Italy
-
IRCCS Ospedale San Raffaele S.r.l.
Milan, 20132, Italy
-
Medizinische Universitat Wien (Medical University of Vienna)
Vienna, 1090, Austria
-
Michalski i Partnerzy Lekarze Spolka Partnerska
Krakow, 31-426, Poland
-
NorthShore University HealthSystem
Glenview, Illinois, 60026, United States
-
Oxford University Hospitals NHS Trust
Oxford, OX3 9DU, United Kingdom
-
Queen Elizabeth University Hospital
Glasgow, G51 4TF, United Kingdom
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
-
Universitatsmedizin Gottingen (UMG) Georg-August-Universitaet
Göttingen, 37075, Germany
-
University Health Network
Toronto, Canada
-
University of Minnesota
Minneapolis, Minnesota, 55414, United States
-
University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Universitätsklinikum Essen
Essen, 45147, Germany
-
Warszawski Uniwersytet Medyczny
Warsaw, 02-097, Poland